Clinical Trial: A Study of D3L-001 as Monotherapy in Subjects With HER2-Positive Advanced Solid Tumors
Study Status: Completed
Recruit Status: RECRUITING
Condition: HER-2 Positive Advanced Solid Tumors
Study Type: INTERVENTIONAL
Official Title: A Phase 1, Open-label Dose Escalation and Dose-Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3L-001 Monotherapy in Subjects With
Brief Summary:
This first-in-human (FIH) study, multi-center, open-label, dose escalation and dose expansion Phase I study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and preliminary anti-tumor activity of D3L-001 in subjects with HER2-positive advanced solid tumors.
Read more